menu
    • menu
    [{"orgOrder":0,"company":"Prime Therapeutics","sponsor":"EMD Serono","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Approved","graph3":"Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prime Therapeutics \/ EMD Serono","highestDevelopmentStatusID":"12","companyTruncated":"Prime Therapeutics \/ EMD Serono"},{"orgOrder":0,"company":"Chord Therapeutics","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Series A Financing","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Undisclosed","graph3":"Chord Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Chord Therapeutics \/ Omega Funds","highestDevelopmentStatusID":"1","companyTruncated":"Chord Therapeutics \/ Omega Funds"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cladribine","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Undisclosed","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Queen Mary University of London \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Queen Mary University of London \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ M.D. Anderson Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ M.D. Anderson Cancer Center"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Immunology","graph2":"Approved","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"EMD Serono \/ Not Applicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ Not Applicable"},{"orgOrder":0,"company":"Chord Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Immunology","graph2":"Preclinical","graph3":"Chord Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chord Therapeutics \/ Merck","highestDevelopmentStatusID":"4","companyTruncated":"Chord Therapeutics \/ Merck"},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Phase IV","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Merck Group \/ Not Applicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cladribine","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Cladribine","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Columbia University","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Columbia University"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Bionxt Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Cladribine","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"Undisclosed \/ BioNxt Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Undisclosed \/ BioNxt Solutions"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Cladribine","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cladribine","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionxt Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cladribine","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionxt Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cladribine","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionxt Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cladribine","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionxt Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Cladribine","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Dispersible","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Cladribine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Bionxt Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Cladribine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Undisclosed \/ BioNxt Solutions","highestDevelopmentStatusID":"14","companyTruncated":"Undisclosed \/ BioNxt Solutions"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cladribine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Merck & Co \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Cladribine

    Menu

    Cladribine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Merck & Co

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Merck & Co

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Merck Doses First Patient in Phase III Oral Cladribine Study for Myasthenia Gravis

                            Details : Mavenclad (Cladribine) is a orally administered DNA synthesis inhibitor. It is being evaluated in for the treatment of Generalized Myasthenia Gravis.

                            Brand Name : Mavenclad

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 29, 2024

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Undisclosed

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Undisclosed

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Bionxt Solutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BioNxt Signs Agreement with Contract Research and Manufacturing Organization

                            Details : The agreement will serve as the foundation for BioNxt's future product development, particularly its pipeline, which includes Cladribine-Generic (cladribine) oral dissolvable drug formulations.

                            Brand Name : Cladribine-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 08, 2024

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Bionxt Solutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bionxt Solutions

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Bionxt Solutions

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Undisclosed

                            Deal Size : $1.6 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            BioNxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement

                            Details : The net proceeds will be used for the development and commercialization of cladribine. It involves targeting the cells of the adaptive immune system on treating multiple sclerosis.

                            Brand Name : Cladribine-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 19, 2024

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Undisclosed

                            Deal Size : $1.6 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bionxt Solutions

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Bionxt Solutions

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $1.6 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            BioNxt Solutions Announces ODF Cladribine Update and Financing

                            Details : The Company intends to use the net proceeds research, development, and commercialization programs, including its proprietary ODF Cladribine dosage form, directed at the multiple sclerosis.

                            Brand Name : Cladribine-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 25, 2024

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $1.6 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bionxt Solutions

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Bionxt Solutions

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioNxt Reports Successful Results From ODF Cladribine PK Study

                            Details : Cladribine, an oral dissolvable film product, is incorporated into DNA strands where it inhibits DNA synthesis and repair, it is being developed for the treatment of Multiple Sclerosis.

                            Brand Name : Cladribine-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 13, 2024

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bionxt Solutions

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Bionxt Solutions

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioNxt Reports Completion of ODF Cladribine PK Study

                            Details : Cladribine-Generic is a ribonucleoside-diphosphate reductase inhibitor. Its orodispersible film is being evaluated in precinical studies for the treatment of Multiple Sclerosis.

                            Brand Name : Cladribine-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 01, 2024

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Bionxt Solutions

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Bionxt Solutions

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioNxt Reports Successful Results From ODF Cladribine Toxicity Study

                            Details : Cladribine-Generic is a ribonucleoside-diphosphate reductase inhibitor. Its orodispersible film is being evaluated in precinical studies for the treatment of Multiple Sclerosis.

                            Brand Name : Cladribine-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 07, 2024

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Bionxt Solutions

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Bionxt Solutions

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $1.1 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            BioNxt Solutions Announces Closing of Final Tranche of Non-Brokered Private Placement

                            Details : The net proceeds will support the development and commercialization of Cladribine, targeting adaptive immune cells while sparing innate cells, for the treatment of multiple sclerosis (MS).

                            Brand Name : Cladribine-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 29, 2024

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $1.1 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Bionxt Solutions

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Bionxt Solutions

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament

                            Details : Cladribine based oral dissolvable drug film (ODF) reformulation is being evaluated for the treatment of Multiple Sclerosis (MS). Preclinical work is underway with comparative pharmacokinetic and local toxicity studies in animal models having already comm...

                            Brand Name : Cladribine-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 20, 2023

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Undisclosed

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Undisclosed

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Bionxt Solutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BioNxt Signs Definitive Agreement for 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformu...

                            Details : Under the agreement, BioNxt acquires intellectual property rights and joint development of an oral dissolvable drug reformulation using the active pharmaceutical ingredient Cladribine.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 13, 2023

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Bionxt Solutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth